- Home
- JANX vs GERN Comparison
JANX vs GERN Comparison
Compare JANX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- GERN
- Stock Information
- Founded
- JANX 2017
- GERN 1990
- Country
- JANX United States
- GERN United States
- Employees
- JANX N/A
- GERN N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- JANX Health Care
- GERN Health Care
- Exchange
- JANX Nasdaq
- GERN Nasdaq
- Market Cap
- JANX 1.4B
- GERN 974.5M
- IPO Year
- JANX 2021
- GERN 1996
- Fundamental
- Price
- JANX $25.15
- GERN $1.32
- Analyst Decision
- JANX Strong Buy
- GERN Buy
- Analyst Count
- JANX 8
- GERN 8
- Target Price
- JANX $90.63
- GERN $3.71
- AVG Volume (30 Days)
- JANX 711.6K
- GERN 9.4M
- Earning Date
- JANX 08-06-2025
- GERN 08-07-2025
- Dividend Yield
- JANX N/A
- GERN N/A
- EPS Growth
- JANX N/A
- GERN N/A
- EPS
- JANX N/A
- GERN N/A
- Revenue
- JANX $9,336,000.00
- GERN $116,293,000.00
- Revenue This Year
- JANX N/A
- GERN $160.12
- Revenue Next Year
- JANX $1,470.82
- GERN $55.01
- P/E Ratio
- JANX N/A
- GERN N/A
- Revenue Growth
- JANX 28.12
- GERN 22264.04
- 52 Week Low
- JANX $22.48
- GERN $1.17
- 52 Week High
- JANX $71.71
- GERN $5.06
- Technical
- Relative Strength Index (RSI)
- JANX 54.41
- GERN 40.66
- Support Level
- JANX $23.52
- GERN $1.36
- Resistance Level
- JANX $24.87
- GERN $1.48
- Average True Range (ATR)
- JANX 1.13
- GERN 0.09
- MACD
- JANX 0.33
- GERN -0.02
- Stochastic Oscillator
- JANX 70.90
- GERN 7.41
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.